Business India ×
  Magazine:
Pharmaceuticals

Published on: Aug. 10, 2020, 1:31 a.m.
Joining the Covid-19 war
  • Habil Khorakiwala. Picture credit: Sanjay Borade

By Sumit Ghoshal. Contributing Editor, Business India

In recent weeks, a great deal of public attention has been focused on the development, clinical trials and manufacture of vaccines against Covid-19. But pharmaceutical industry experts are acutely aware that even bigger challenges are awaiting them once the vaccine manufacture actually begins.

One of these is the delicate task of filling the bulk vaccine produced in large quantities into smaller containers such as single-dose ampoules or multi-dose vials.

Thus a major consignment of a vaccine might be sufficient to protect thousands of people against a particular infection (whether Covid-19 or any other virus disease such as polio). But it must still be transformed into much smaller batches before it can be administered to an individual person. This is similar to the process of creating pharmaceutical formulations from bulk drugs that are sold in huge drums or forms of other packaging.

With its long experience in producing injectable medicines of different varieties, drug major Wockhardt has now decided to offer its services in manufacturing small multi-dose vials of vaccines against Covid-19. To this end, it has reached an agreement with the UK government to convert the AstraZeneca version of the vaccine into smaller containers. This activity will be carried out in Wockhardt’s Wrexham production facility in Northern Wales.

Addressing a news conference last fortnight to announce the pact, Dr Habil Khorakiwala, chairman of Wockhardt, clearly pointed out that his company was not planning to produce the vaccine itself, as Serum Institute, Bharat Biotech and others were going to do. Wockhardt would also not sell its output directly in the market, either in the UK or in any other country.

Their entire production would be sold back to AstraZeneca who would then be at complete liberty to market it through its own distribution channels. Incidentally, AstraZeneca has concluded agreements with nearly a dozen companies and even some non-profit organisations such as CEPI (Coalition for Emergency Preparedness and Innovation) for distribution of their vaccine in different parts of the world.
 
Dr Khorakiwala also said that they would be open to similar agreements to any other company, in India or elsewhere for the conversion of bulk quantities of any other vaccine as well. Thus while they had reached their first agreement with the UK, they would be willing to offer their services to any company that requested it.

According to Dr Murtaza Khorakiwala, managing director and global CEO of Wockhardt, “The arrangement with the UK government for manufacturing vaccines for Covid-19 showcases our global strength in world-class sterile injectable facilities and capacity. With four decades of expertise and experience behind us we are able to quickly scale to manufacture and assist in mitigating the worldwide impact of Covid-19.”

Various UK officials also made appreciative remarks with reference to the Wockhardt arrangement. Thus Kate Bingham, Chair of UK Vaccines Task Force said, “Never before have we needed to find and manufacture a vaccine at this speed and scale in order to protect the UK population. We have made significant progress in securing a diverse portfolio of potential vaccines and treatments for Covid-19, adding a fourth vaccine candidate from GSK and Sanofi last fortnight.

However, discovering a successful vaccine is only part of the solution, we also need to be able to manufacture it. The agreement with Wockhardt will boost our capability to ensure that from the moment a successful vaccine is identified we will be able to produce the quantities of vaccine required, as quickly as possible, for the people who need it.”

Though the Wockhardt chairman refused to say how much revenue would be added to the company’s topline, it is probably going to be quite substantial. As word of the pact filtered through to the media, the company’s share price soared by nearly 15 per cent.

Wockhardt has reported a noticeable downturn in its business operations in almost every part of the world and was constrained to divest a sizeable portfolio of its products to Dr Reddy’s Laboratories just about a month ago (Business India: June 29-July 12). The Wockhardt news release issued in that context said that the sale was intended to shore up the company’s balance sheet and to make sufficient funds available for its forthcoming patented product – WCK 777. The new antibiotic product has recently been designated as a QIDP (Qualified Infectious Disease Product) by the USFDA.

Don't miss this

Cover Feature

Sensex @ 50000

Ahead of the budget, another landmark for the market…

Special Report

The broad canvas of start-up activity

The more start-ups sprout, the greater is the opportunity for new ideas to bloom

Focus

India's vaccine logistics

New lessons await the logistics players who are engaged in providing relief to the country from Covid-19

Corporate Report

Cello marches ahead

The Group positions itself strongly in the houseware market

Our letter to you, once a week.
Register with The CSR Weekly for free!

E-MAGAZINE
BI 1092 Digital-Sensex @ 50000
Predictions 2021: Times they are a-changing
Super 100
FROM THIS ISSUE

Corporate Report

Column

Corporate Report

States

F&B

Selections

Social Responsibility

Environment

Tata Motors launches a 'Go Green' initiative

Published on Dec. 23, 2020, 10:34 a.m.

The company will plant a sapling for the sale of every new commercial vehicle

Women Empowerment

Tata Starbucks ties up with Educate Girls to empower women

Published on Dec. 2, 2020, 3:10 p.m.

The partnership aims to provide volunteering and educational support to those who have relocated to urban cities from villages

Environment

Indian Oil has a social initiative for a clean and green world

Published on Nov. 25, 2020, 2:53 a.m.

The public sector company is planting a tree for every retail customer visit during its TreeCheers campaign period

Education

MG Motor India launches Dakshata for students

Published on Nov. 17, 2020, 8:25 a.m.

The car company extends global tech expertise to students through the launch of ‘Dakshata’ in partnership with ASDC and Autobot India

Climate Change

Energy

Husk Power uses rice husk to generate electricity in rural India

Published on Dec. 23, 2020, 9:32 a.m.

The company provides grid compatible and reliable power to customers

Energy

Smart Joules and energy saving solutions

Published on Nov. 17, 2020, 10:17 a.m.

The company's full-stack solution guarantees 15 per cent energy savings and zero upfront costs to the customer

Green Buildings

The GreenPro Ecolabel Standard for steel rebars will help a green built environment

Published on Nov. 5, 2020, 9:33 a.m.

Eight companies have already achieved CII’s Green Building Congress 2020 new standard

Land Use

Building resilience for an urbanising India

Published on Oct. 30, 2020, 10:25 a.m.

Climate change with its range of impact on regions and geographies needs the participation of communities

Stay ahead of the times.
Register with The Climate Change Weekly for free!